Dignitana AB Publishes Q2 2021 Interim Report
US treatment growth drives 23 percent increase in net revenueFinancial highlights Q2 2021 · Net sales amounted to 14 MSEK (11,4), an increase of 23 percent over the same period 2020. · Operating result amounted to -9,4 MSEK (-9,0) · Net result after financial items amounted to -9,7MSEK (-9,5) · Earnings per share were -0,15 SEK (-0,17) · Cash Balance amounted to 36,3 MSEK (7,5) · Average Daily Treatment Revenue (ADTR)* was 163 TSEK (109), an increase of 49 percent over the same period in 2020. Financial highlights January – June 2021 · Net sales amounted to 27,